1-3 of 3
Thierry Facon, MD, PhD
Close
Sort by
Journal Articles

Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyéLome (IFM) Krd Phase II Study

Murielle Roussel, MD, Valerie Lauwers-Cances, MD, Nelly Robillard, PhD, Karim Belhadj, MD, Thierry Facon, MD PhD, Laurent Garderet, MD, Martine Escoffre, MD, Brigitte Pegourie, MD, Lotfi Benboubker, MD PhD, Denis Caillot, Cecile Fohrer, MD, Philippe Moreau, Xavier Leleu, Herve Avet-Loiseau, MD PhD, Michel Attal
Journal: Blood
Blood (2016) 128 (22): 1142.
https://doi.org/10.1182/blood.V128.22.1142.1142
Published: 2016
Journal Articles

FGFR3 Tyrosine Kinase Inhibitor AB1010 as Treatment of t(4;14) Multiple Myeloma.

Bertrand Arnulf, MD, PhD, David Ghez, MD, Veronique Leblond, MD, PhD, Sylvain Choquet, MD, PhD, Karim Belhadj, MD, Margaret Macro, MD, Didier Bouscary, MD, PhD, Thierry Facon, MD, PhD, Philippe Moreau, MD, PhD, Arnaud Jaccard, MD, PhD, Jean Soulier, MD, PhD, Lionel Karlin, MD, Olivier Hermine, MD, PhD, Jean-Paul Fermand, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 413.
https://doi.org/10.1182/blood.V110.11.413.413
Published: 2007
Journal Articles

Mutation Status of Imatinib Mesylate-Resistants CML Patients and Clinical Outcomes: A French Multicenter Retrospective Study for the fiLMC Group.

Selim Corm, MD, Franck Nicollini, MD, Dominique Borie, MD, Nathalie Sorel, MD, Thibault Leguay, MD, Sandrine Hayette, PhD, Thierry Facon, MD, PhD, Laurence Roy, MD, Stephane Giraudier, MD, PhD, Gerald Marit, MD, Claude Preudhomme, MD, PhD, Mauricette Michalet, MD, PhD, Francois-Xavier Mahon, MD, PhD, Michel Thuilliez, MD, PhD, Francois Guilhot, MD, PhD, Catherine Roche-Lestienne, PhD
Journal: Blood
Blood (2004) 104 (11): 275.
https://doi.org/10.1182/blood.V104.11.275.275
Published: 2004